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1. Introduction
Computed tomography (CT) constitutes  the gold standard for  quantification of  vascular
calcification  (VC)  and,  being  the  most  effective  and widely  available  with  reproducible
measurements, is also useful for monitoring progression as well as assessing the effect of
therapeutic strategies to modify progression [1] [2]. VC has a significant effect in cardio‐
vascular  diseases  on  dialysis  patients.  Tanne  et  al.  [3]  focused  on  calcification  of  the
thoracic aorta and found that it associated with coronary and valvular calcification in hy‐
pertensive  patients.  In  the  Calcification  Outcome  in  Renal  Disease  (CORD)  study,  ab‐
dominal aortic calcification was found to have the predictive value for the occurrence of
cardiovascular  events  and mortality  in  dialysis  patients  [4].  Coll  et  al.  [5]  reported that
VC in large, conduit arteries was prevalent in patients on dialysis patients, and that age,
dialysis  vintage,  past  medical  history  of  cardiovascular  disease,  atherosclerosis  and  in‐
flammation were variable significantly influencing VC. From these studies,  it  is  suggest‐
ed that  VC occurs  in  vessels  of  various diameters.  However,  no definitive studies  have
determined the significance of VC in different vessels in patients receiving dialysis thera‐
py  until  the  present  time.  Moreover,  there  have  been  few studies  examining  a  relation
between semi-quantitative measures of VC and their contributing factors. The aim of this
work presented here is to examine a relation between semi quantitatively measured calci‐
fication of three major vessels, the thoracic aorta, the abdominal aorta and the iliac arter‐
ies  and  several  known  contributing  factors  to  VC  such  as  underlying  diseases,  age,
gender,  vintage  of  dialysis,  values  of  serum  calcium  and  phosphate,  use  of  calcium-
based phosphate binders and so on.
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2. Methods
All HD patients received three dialysis sessions of at least 4 h duration per week. HD was
performed using low flux polysalphose dialyhsers (1.5-2.0 m2 APS Asahi Medical R Tokyo,
Japan). All HD patients were dialyzed using bicarbonate-bound 1.25 mmol/L, calcium and
134 mmol/sodium containing dialysate. Patients were all dialysed at the Dialysis Unit of Iru‐
madai Hospital.
This was an observational and cross-sectional study that included 79 hemodialysis patients
at the Dialysis Unit of Irumadai Hospital, who gave their informed consent to enroll in this
study. The inclusion criteria were patient providing informed consent, age ≥ 40 years and
duration of dialysis ≥ 1 year. Exclusion criteria were significant fetal diseases that were esti‐
mated to reduce life expectancy to < 6 months and patients in whom it was impossible to
measure CT scan.
The recorded cardiovascular history and smoking status were obtained. The following base‐
line biochemical data were obtained; serum calcium, phosphorus, intact parathyroid hor‐
mone, albumin, total cholesterol, low-density lipoprotein cholesterol. Data on weight,
height, body mass index and duration of dialysis and use of medications: phosphate bind‐
ers, vitamin D, statins, erythropoietin and antihypertensive agents. Clinical characteristics
and laboratory variables including dual-energy x-ray absorptiometry and pulse wave veloc‐
ity. This study complies with the Declaration of Helsinki and was in agreement with the
guidelines approved by the ethics committee at the institution.
2.1. Computed tomography
CT scan of the aorta and arteries was performed with a 16-detector CT scan {Prime Purpose
MDCT (GE Healthcare, Milwaukee, WI USA)}. Scanning time was 0.5 s for two contiguous
1.25 mm sections and 20±5 seconds for the entire zone of interest. Examination was per‐
formed during a single, unforced, withheld inspiration. During scanning with the tube rotat‐
ing at 2 rotation/second and the table moving at 55 mm/s with a 1:1.375 scanning pitch,
images were obtained with an effective section thickness of 10 mm. Scanning was performed
with 120 kVp and 350 mAs, standard resolution, and a 28-36 cm field of view. The total du‐
ration of the procedure was 5min. The range of CT scan was illustrated in Fig. 1.
2.2. Evaluation of thoracic and abdominal aorta and iliac artery
Volume acquisitions were analyzed using Volume Viewer software (GE Healthcare). The
thoracic and abdominal aorta were segmented manually. In order to reduce errors due to
noise, a cut-off of 130 Housefield Unit (HU) was applied. The total calcification volume was
calculated as the sum of all voxels in the remaining volume.
2.3. Biochemistry
Blood samples were collected at monthly intervals. The results presented here were time-
averaged results from the preceding 6 months prior to the CT scan.
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Figure 1. A range of computed tomography (CT) scan is illustrated.
2.4. Blood pressure
Three blood pressure (BP) recording were taken suing automated device.
2.5. Statistics
Data are expressed as means ± SD. Using variables found to be significant in the univariate
analysis and potential confounders, we applied forward stepwise logistic regressions, in or‐
der to determine which of these variables were most significantly associated with calcifica‐
tion of the thoracic and abdominal aorta and the arteries of the lower limbs. F-to-Remove
was set at 2.9. P<0.05 was considered as significance.
3. Results
3.1. Patients characteristics
The underlying kidney diseases were diabetic nephropathy [32], chronic glomerulonephritis
(23), nephrosclerosis, polycystic kidney disease (3) and others (12).
Baseline demographics and laboratory and hemodynamic values of the study population
are shown in Tables 1, 2 and 3 and current medications used are listed in Table 4.
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Table 1. Characteristics of patients
Table 2. Hemodynamic markers
Table 3. Serum markers
Table 4. Current medications of the study population
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3.2. Calcification of vessels
In Table 5, the average of calcification scores is shown.
All  three  lesions  correlated  significantly  with  each  other.  Stepwise  regression  was  ap‐
plied  in  which  the  independent  variables  were  identified  from  the  univariate  analyses.
Significant  associations  were  seen  for  the  following:  the  prevalence  of  calcification;  the
thoracic aorta with period of dialysis, elevations of both systolic and diastolic blood pres‐
sure and levels of serum albumin (Table 6); in the abdominal aorta with age, presence of
diabetes, and calcium supplement (Table 7); arteries of the lower limbs with presence of
diabetes mellitus, use of sevelamer and cinacalcet and serum levels of intact parathyroid
hormone and albumin (Table 8).
Table 5. Calcification scores of thoracic aorta, abdominal aorta and iliac artery
SBP: systolic blood pressuer, DBP: diastolic blood pressure
Table 6. Significant correlations with calcification of thoracic aorta
DM: diabetes mellitus, CaCO3: oral administration (g/day), Vitamin D: oral administration (μg/day)
Table 7. Significant correlations with calcification of abdominal aorta
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DM: diabetes mellitus, Savelamer: oral administration (g/day), Cinacalcet: oral administration (mg/day)
Table 8. Significant correlations with calcification of lower limb
4. Discussion
In the present study, we found that the contributing factors to VC were different in the dif‐
ferent vessels. The development and progression of VC is a multifactorial process. Potential‐
ly differing factors may exert their maximum influence at either the predisposition,
initiation and continuation phases of the process. The multivariate analysis performed on
these data attempt to elucidate which factors might be most significant to the development
of VC. In the present study, age, duration of HD, systolic and diastolic BP, presence of DM
serum levels of Ca, intact PTH, calcium modulating drugs and albumin contributed differ‐
ently in the different vessels. Albumin was negatively correlated with the severity of VC.
This suggests that a characteristic state of low albumin as seen in malnutrition, inflamma‐
tion or atherosclerosis complex is most important, as suggested by Wang et al. [6]. Factors
shown to predict VC in the current study included older age, longer dialysis vintage, diabe‐
tes, higher concentrations of serum phosphorus and calcium are associated with more exten‐
sive VC among patients on HD and result partially consistent with those reported
previously [7] [8] [9] [10].
Adler et al [11] demonstrated a strong association of coronary calcification and calcification
of the thoracic aorta on spiral CT. The aortic calcification signifies a higher probability of
coronary atherosclerosis and ischemic stroke (Cerebrovascular disease). Also, Tanne et al.
[3] found that severe calcification in descending aorta is a predictor of ischemic cerebrovas‐
cular events. Calcification of the thoracic aorta is not a direct causative factor for embolic
stroke, but rather a marker of increased burden of vascular (atherosclerotic disease) disease
[12]. However, Honkanen et al. [4] reported that although the duration of HD correlates
with calcification in coronary [1], carotid and peripheral arteries [7], the association is less
clear in the thoracic arteries [8].
In the present study, calcification of the thoracic aorta had a strong association with dialysis
vintage, systolic and diastolic BP and albumin, which are a major factors contributing to car‐
diovascular diseases. From these data, it is possible that severe calcification of the thoracic
aorta is produced by hemodynamic, malnutrition and uremia in combination.
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Abdominal aorta calcification has been well studied, has been associated with an increase
risk  of  cardiovascular  morbidity  and mortality  in  patients  with  HD [13].  Hanada et  al.
[14] proposed that the section of the aorta chosen for measuring the semiquantitative cal‐
cification score is suitable for evaluation of the severity of VC because the site is associat‐
ed with turbulent flow and is susceptible to development of atheroma. The chosen site is
also simple to investigate radiologically since it is in a significant part of the aorta and is
vertical  to  the  transverse  section.  In  the  present  study,  VC of  the  abdominal  aorta  was
correlated with the presence of  diabetes,  which is  a  well-known atherosclerotic  risk fac‐
tor. In addition, the factors relating with calcium-phsophate modulation, such as concen‐
trations  of  calcium,  PTH  and  so  on  are  frequently  evoked  as  the  principal  causes
associated with vascular  remodeling and/or  arterial  calcifications  [15]  [16].  Guerin  et  al.
[17] reported that in HD patients,  there is  an association between the presence of aortic
calcification and increased Ca x P products.  In contrast,  Arad et al.  did not find the se‐
rum concentrations of calcium, 1,25-Vit D, and PTH to be associated with the presence of
arterial calcifications [18]. Besides, the amount of CaO3  prescribed as a phosphate binder
was independently associated with the score of vascular calcifications. One of the adverse
effects of calcium based phosphate binders is hypercalcemia, which may in turn result in
arterial calcification. It is therefore likely that development of VC of the abdominal aorta
is associated with calcium and phosphorus regulation in HD patients. Moreover, mineral
bone disease-related factors such as serum calcium, phosphorus and PTH are thought to
be strongly associated with the severity of VC in dialysis patients [19] [20].
Sigrist et al. [21] described a simple, sensitive low radiation dose technique as an alternative
to coronary artery and aortic measurements to quantify a calcification score for the superfi‐
cial femoral artery (SFA). The sector of artery chosen for this study is ideal as it avoids major
bifurcations and arterial branching, and therefore, obvious site for turbulent flow and the
development of atheroma. In the present study, factors contributing to VC of the iliac arter‐
ies are similar with those of the abdominal aorta.
In the Calcification Outcome in Renal Disease (CORD) study, 19% of patients had no visible
calcification in their abdominal aorta [4]. These findings are partially in line with certain pre‐
vious observations and it has been suggested that these individuals rarely develop calcifica‐
tion at follow-up [22] [8] [23]. In the present study, we did not find these individuals.
Recently, further reports from CORD study provided a new evidence that no coronary [24]
or thoracic aortic calcification at baseline, but their calcification developed during 2 years of
observation and was most prevalent in those receiving calcium-containing binders. Besides,
retrospective and cross-sectional data have given contradicting results with some publica‐
tion showing a contribution of Vit D to VC [15], whereas others do not support this conten‐
tion [25]. It is therefore unlikely that HD patients receiving calcium-containing binders and
Vitamin D analogues have no VC of the vessels.
Recently Allison et al. [26] demonstrated that in terms of extent of calcification, the iliac ar‐
teries showed the strongest association for all mortality and end points, consistent with the
well-known association between the severity of peripheral artery disease and both CVD and
total mortality [27].
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In addition, they concluded [26] that higher levels of calcium in different vascular beds are
associated not only with CVD mortality but also with non-CVD and total mortality and that
location of the arterial calcification appears to be relevant to the strength of the association
with mortality, and the CVD risk factors appear to mediate some of this association.
4.1. Study limitations
First, the imaging methods used in this study did not distinguish the two types of VC (pathy
calcification of the intima and calcification of the media). As is known, mineral metabolism
disturbances link specifically with medial rather than intimal V and intima calcification as‐
sociates with atherosclerosis. Second, our studies was cross-sectional, it does not directly
show how detection of VC in various vessels predict incident cardiovascular events in the
dialysis patients. Third, VC represents the result of long-standing atherosclerotic and calcifi‐
cation processes. It is unclear whether the steady-state of serum chemistry such as calcium,
phosphate, intact PTH concentrations measured in this study accurately represents patho‐
logical process that occurred when VC was developing.
5. Conclusion
Presence and extension of VC in thoracic and abdominal aortas and lower limbs might be
regulated in complex manner and caution should be needed to use these variables as a
marker of the burden of vascular disease. The associations between calcified atherosclerosis
and mortality differ by vascular bed, suggesting that the location and severity of calcifica‐
tion in different vascular beds provide unique information for mortality.
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